Use of pioglitazone in the treatment of diabetes: Effect on cardiovascular risk

Vascular Health and Risk Management

Volumn 9, Issue 1, 2013, Pages 429-433

  Zou, Cong ^a   Hu, Honglin ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

Cardiovascular risk; Diabetes; Pioglitazone

Indexed keywords

C REACTIVE PROTEIN; GELATINASE B; GLIMEPIRIDE; GLIMEPIRIDE PLUS PIOGLITAZONE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; PIOGLITAZONE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDIN SYNTHASE; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA; TRIACYLGLYCEROL;

ADD ON THERAPY; ADVERSE CARDIOVASCULAR OUTCOME; ARTERIAL WALL THICKNESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CORONARY ARTERY ATHEROSCLEROSIS; DIABETIC DYSLIPIDEMIA; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; MICROALBUMINURIA; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PODOCYTE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; REVIEW; RISK BENEFIT ANALYSIS; VASCULITIS;

CARDIOVASCULAR RISK; DIABETES; PIOGLITAZONE;

ADMINISTRATION, ORAL; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84889873944     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S34421     Document Type: Review

References (38)

1. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab. 2012;23(5): 205-215.
2. Kung J, Henry RR. Thiazolidinedione safety. Expert Opin Drug Saf. 2012;11(4):565-579.
3. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-2135.
4. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180-1188.
5. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med. 1998;338(13):916-917.
6. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471.
7. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials. Lancet. 2007;370(9593):1129-1136.
8. Dorkhan M, Dencker M, Stagmo M, Groop L. Effect of pioglitazone versus insulin glargine on cardiac size, function and measures of fluid retention in patients with type 2 diabetes. Cardiovasc Diabetol. 2009;8: 15-20.
9. Singh S, Loke Y, Furberg C. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189-1195.
10. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROACTIVE Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289.
11. Fanarow GC. Approach to the management of diabetic patients with heart failure: role of thiazolidinediones. Am Heart J. 2004;148(4): 551-558.
12. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin and outcomes in older patients with diabetes and heart failure. An observational study. Circulation. 2005;111(5):583-590.
13. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229-234.
14. Brener SJ, Lytle BW, Casserly IP, Topol EJ, Lauer MS. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary disease and high-risk features. Circulation. 2004;109(19):2290-2295.
15. Scholte AJ, Schuijf JD, Kharagjitsingh AV, et al. Prevalence of coronary artery disease and plaque morphology assessed by multi-slice computed tomography coronary angiography and calcium scoring in asymptomatic patients with type 2 diabetes. Heart. 2008;94(3):290-295.
16. Waller BF, Palumbo PJ, Lie JT, Roberts WC. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years: analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjects. Am J Med. 1980;69(4):498-506.
17. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281(14):1291-1297.
18. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561-1573.
19. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. Hyperinsulinemic microalbuminuria: a new risk indicator for coronary heart disease. Circulation. 1995;91(3):831-837.
20. Eastman RC, Keen H. The impact of cardiovascular disease on people with diabetes: the potential for prevention. Lancet. 1997;350 Suppl 1: SI29-SI32.
21. Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes. 1992;41(6):736-741.
22. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004;27(1):141-147.
23. Agrawal B, Wolf K, Berger A, Luft FC. Effect of antihypertensive treatment on qualitative estimates of microalbuminuria. J Hum Hypertens. 1996;10(8):551-555.
24. Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism. 2001;50(10):1193-1196.
25. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992;15(7):820-825.
26. Haffner SM. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004;27 Suppl 1:S68-S71.
27. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28(7):1547-1554.
28. Berhanu P, Kipnes MS, Khan MA, et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res. 2006;3(1):39-44.
29. Davidson M, Meyer PM, Haffner S, et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation. 2008;117(16):2123-2130.
30. Derosa G, Cicero AF, D'Angelo A, et al. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clin Ther. 2006;28(5):679-688.
31. Hanefeld M, Marx N, Pfützner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol. 2007;49(3):290-297.
32. Karagiannis E, Pfützner A, Forst T, et al. The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions. Diabetes Technol Ther. 2008;10(3): 206-212.
33. Forst T, Karagiannis E, Lübben G, et al. Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis. 2008;197(1):311-317.
34. Honda T, Kaikita K, Tsujita K, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders. J Mol Cell Cardiol. 2008;44(5):915-926.
35. Li J, Lang MJ, Mao XB, Tian L, Feng YB. Antiapoptosis and mitochondrial effect of pioglitazone preconditioning in the ischemic/reperfused heart of rat. Cardiovasc Drugs Ther. 2008;22(4):283-291.
36. Ye Y, Lin Y, Manickavasagam S, Perez-Polo JR, Tieu BC, Birnbaum Y. Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice. Am J Physiol Heart Circ Physiol. 2008;295(6):H2436-H2446.
37. Wang H, Zhu QW, Ye P, et al. Pioglitazone attenuates myocardial ischemia-reperfusion injury via up-regulation of ERK and COX-2. Biosci Trends. 2012;6(6):325-332.
38. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168(8):820-825.